Advertisement

Topics

Companies Related to "EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease" [Most Relevant Company Matches] RSS

19:57 EDT 16th October 2018 | BioPortfolio

Here are the most relevant search results for "EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease" found in our extensive corporate database of over 50,000 company records.

Showing "EndocardialVascularEndothelialGrowth Factor VEGF Gene Therapy Treatment Severe Coronary" Companies 1–25 of 4,600+

Extremely Relevant

Gene Therapy Systems (GTS)

Gene Therapy Systems, Inc. (GTS) designs, develops and commercializes gene therapy products along with other molecular biological reagents for scientists specializing in gene therapy research. GTS is the only company in the biotechnology reagent business that primarily focuses on gene therapy related products.


Collateral Therapeutics Incorporated

Collateral's initial non-surgical gene therapy products under investigation are designed to promote and enhance angiogenesis, a natural biological process which results in the growth of additional blood vessels, to increase levels of blood flow to oxygen-deprived tissues. The Company's angiogenic products are administered using methods of gene therapy based on non-surgical adenoviral vector delive...

Relevant

Neurologix

Neurologix, Inc., a leader in the development of innovative therapies for the brain and central nervous system, utilizes gene therapy and other novel technologies. The central nervous system ("CNS") is a new and particularly exciting target for gene therapy because its unique properties prevent the successful treatment of many neurological disorders by conventional means such as drug therapy and s...


AVEO Oncology & Astellas Pharma Inc.

In February 2011, AVEO and Astellas entered into a worldwide agreement to develop and commercialize tivozanib outside of Asia for the treatment of a broad range of cancers. Tivozanib, AVEO's lead investigational drug, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimi...

Voyager Therapeutics, Inc.

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniqu...

Avigen

Avigen is a leader in the development of gene therapy products derived from adeno-associated virus ("AAV") for the treatment of inherited diseases. Avigen's proposed gene therapy products are designed for in vivo administration to achieve the production of therapeutic proteins within the body. Avigen has honed it's strategic focus on developing a broad-based proprietary gene delivery technology, A...

Nuvelo

Nuvelo, Inc. is a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes several acute cardiovascular and oncology programs. The cardiovascular portfolio includes three programs: alfimeprase, a direct acting thr...

Sunshine Heart, Inc.

Sunshine Heart (ASX:SHC) is a global medical device company committed to novel cardiac and coronary therapy. The company is currently developing the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-...

PLC Systems

PLC is a global leader in the development of products for performing a revolutionary new surgical procedure known as transmyocardial revascularization (TMR). TMR offers a completely new medical treatment option for patients who suffer from severe coronary artery disease. Coronary artery disease is the leading cause of death in the United States. Working with leading researchers and premier heart...

bluebird bio, Inc.

bluebird bio is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patientâ...

RheoGene Inc

RheoGene is developing the RheoSwitch® Therapeutic System (RTS) for cell and gene therapy. RTS delivers therapeutic gene products in the patient to the right place, at the right time, and at the right dose. Despite advances in the understanding of the genetic and molecular basis of disease, there are no approved gene therapy products on the market today, in part because of the unmet need for effi...

AMT B.V

Founded in 1998 on the initiative of researchers from the Academic Medical Center (AMC) in Amsterdam, AMT has become a leader in the field of human gene therapy. A pioneer in the development of gene therapy AMT has used its scientific know-how and expertise to build up a strong research and clinical development program filling an unmet medical need for therapy of severe (orphan) diseases in the fo...

Karolinska Institute

The primary objectives of the European Society of Gene Therapy (ESGT) are to promote basic and clinical research in gene therapy, to promote education and the exchange of information and technology related to gene transfer and therapy and to serve as a professional adviser to the community and to the regulatory bodies in Europe.

Transgene

TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited diseases. The Company's proprietary technology platform consists of five vector families including three of viral origin - adenovirus, retrovirus, vaccinia virus - and two of non viral origin - cellula...

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AA...

Rocket Pharmaceuticals, Ltd.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”) is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (A...

Globe Laboratories

Globe Labs manufactures and sells high quality, low cost human therapeutic proteins, human growth hormones, enzymes, research laboratory cytokines, chemokines & their respective inhibitors/antagonists for research and veterinary use. We are also manufacturers of bulk quantities for other pharmaceutical companies worldwide. Globe Labs is proud to have the largest antagonist product list in the worl...

INHERINET

INHERINET (Gene Therapy of Hematopoietic Stem Cells for Inherited Diseases), an initiative founded by seven European research institutions, accumulates the expertise of biomedical scientists who have a strong background in the development of all platform technologies required for successful gene therapy:State-of -the-art design and production of retroviral and lentiviral gene transfer vectors Basi...

NightstaRx Limited

Nightstar is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and for which there are no other treatment options. Nightstar’s lead program, NSR-REP1, is being developed ...

Genetix Pharmaceuticals, Inc.

Genetix Pharmaceuticals, Inc. is an emerging leader in treatments for severe genetic disorders based on a breakthrough gene therapy platform that uses a patient’s own genes to treat his/her disorder. Taking stem cells from a patient’s own bone marrow, Genetix uses a proprietary lentiviral technology to modify the genes and deliver corrective stem ...

Accredo Nova Factor

For more than 20 years, Accredo Nova Factor has provided nationwide distribution and pharmaceutical care management for the biopharmaceutical industry. Accredo Nova Factor currently has 15 product lines that are dispensed from its specialty pharmacy headquarters in Memphis, Tenn. The products are usually shipped overnight to the patients' homes, where patients are trained to reconstitute and self-...

MOLOGEN AG

MOLOGEN is specializing in selected areas of Molecular Medicine. Our areas of competence are gene expression, gene therapy and bioinformatics. We are dedicated to the development of DNA expression and delivery technologies for human and veterinary applications, leading to products for gene therapy, and prophylactic and therapeutic DNA-based vaccines

Dimension Therapeutics

Dimension Therapeutics is a gene therapy company focused on developing novel therapies to treat rare diseases. Launched by Fidelity Biosciences in 2013, the Dimension team comprises biotech industry veterans and renowned thought leaders in gene therapy and rare diseases. The company is focused on building its adeno-associated virus (AAV) therapeutic discov...

Rcadia Medical Imaging Ltd.

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The COR Analyzer...

Rcadia Medical Imaging

Rcadia Medical Imaging develops and markets automated image processing software products for blood vessel analysis in patients with suspected cardiovascular disease. The company's first FDA-cleared product, the COR Analyzer® System, provides fully automated, real-time analysis of Coronary CT angiography to enable the practical application of cCTA in detecting severe coronary artery disease. The C...


More From BioPortfolio on "EndocardialVascularEndothelialGrowth Factor D(VEGF-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks